These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21050910)

  • 1. Measurement of inverse agonism in β-adrenoceptors.
    Taira CA; Monczor F; Höcht C
    Methods Enzymol; 2010; 485():37-60. PubMed ID: 21050910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Techniques for studying inverse agonist activity of antidepressants at recombinant nonedited 5-HT(₂C-INI) receptor and native neuronal 5-HT(₂C) receptors.
    Seimandi M; Bockaert J; Marin P
    Methods Enzymol; 2010; 485():61-79. PubMed ID: 21050911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo.
    Barki-Harrington L; Luttrell LM; Rockman HA
    Circulation; 2003 Sep; 108(13):1611-8. PubMed ID: 12963634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author's transl)].
    Lemmer B
    Herz; 1982 Jun; 7(3):168-78. PubMed ID: 6124492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agonist-induced modulation of inverse agonist efficacy at the beta 2-adrenergic receptor.
    Chidiac P; Nouet S; Bouvier M
    Mol Pharmacol; 1996 Sep; 50(3):662-9. PubMed ID: 8794908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-agonist-induced constitutive beta(2)-adrenergic receptor activity in bovine tracheal smooth muscle.
    de Vries B; Meurs H; Roffel AF; Elzinga CR; Hoiting BH; de Vries MM; Zaagsma J
    Br J Pharmacol; 2000 Nov; 131(5):915-20. PubMed ID: 11053211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors.
    Aloyo VJ; Berg KA; Spampinato U; Clarke WP; Harvey JA
    Pharmacol Ther; 2009 Feb; 121(2):160-73. PubMed ID: 19109993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
    Kenakin T
    Mol Pharmacol; 2004 Jan; 65(1):2-11. PubMed ID: 14722230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inverse agonist activity of beta-adrenergic antagonists.
    Chidiac P; Hebert TE; Valiquette M; Dennis M; Bouvier M
    Mol Pharmacol; 1994 Mar; 45(3):490-9. PubMed ID: 7908406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand-independent negative chronotropic responses of rat and mouse right atria to beta-adrenoceptor antagonists.
    Varma DR
    Can J Physiol Pharmacol; 1999 Dec; 77(12):943-9. PubMed ID: 10606440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative properties of various beta-blockers, with an outlook to the future.
    van Zwieten PA
    Clin Physiol Biochem; 1990; 8 Suppl 2():18-27. PubMed ID: 1982758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of inverse agonism for the angiotensin II type 1 receptor.
    Akazawa H; Yasuda N; Miura S; Komuro I
    Methods Enzymol; 2010; 485():25-35. PubMed ID: 21050909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of inverse agonism of the cannabinoid receptors.
    Fong TM
    Methods Enzymol; 2010; 485():139-45. PubMed ID: 21050915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inverse agonism: from curiosity to accepted dogma, but is it clinically relevant?
    Parra S; Bond RA
    Curr Opin Pharmacol; 2007 Apr; 7(2):146-50. PubMed ID: 17284360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutive activity of the human beta(1)-adrenergic receptor in beta(1)-receptor transgenic mice.
    Engelhardt S; Grimmer Y; Fan GH; Lohse MJ
    Mol Pharmacol; 2001 Oct; 60(4):712-7. PubMed ID: 11562432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Getting to the heart of asthma: can "beta blockers" be useful to treat asthma?
    Bond RA; Spina D; Parra S; Page CP
    Pharmacol Ther; 2007 Sep; 115(3):360-74. PubMed ID: 17681610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Beta-adrenergic receptor blockers in clinical practice].
    Czuriga I; Edes I
    Orv Hetil; 2004 Sep; 145(38):1951-60. PubMed ID: 15535106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions of agonists and antagonists with beta-adrenergic receptors.
    Molinoff PB; Weiland GA; Heidenreich KA; Pittman RN; Minneman KP
    Adv Cyclic Nucleotide Res; 1981; 14():51-67. PubMed ID: 6116391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential inverse agonism at the human muscarinic M₃ receptor.
    Casarosa P; Kiechle T; Bakker RA
    Methods Enzymol; 2010; 485():81-101. PubMed ID: 21050912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural requirements for inverse agonism and neutral antagonism of indole-, benzimidazole-, and thienopyrrole-derived histamine H4 receptor ligands.
    Schneider EH; Strasser A; Thurmond RL; Seifert R
    J Pharmacol Exp Ther; 2010 Aug; 334(2):513-21. PubMed ID: 20484153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.